Alka Chaubey - Feb 15, 2023 Form 4 Insider Report for Bionano Genomics, Inc. (BNGO)

Role
Chief Medical Officer
Signature
/s/ R. Erik Holmlin, Attorney-in-Fact
Stock symbol
BNGO
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 06:21 PM
Previous filing
Feb 15, 2022
Next filing
Sep 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BNGO Common Stock Award $0 +120K +2503.13% $0.00 125K Feb 15, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNGO Stock Option (Right to Buy) Award $0 +560K $0.00 560K Feb 15, 2023 Common Stock 560K $1.63 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
F2 Includes 2,285 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 2,509 shares acquired under the ESPP on December 10, 2022.
F3 The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.